Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Statin therapy may target both hypercholesterolemia and cholestasis in primary biliary cirrhosis (PBC). However, little is known about the efficacy and safety of statins in PBC. The aim of this single-center study was therefore to prospectively examine the effects of atorvastatin on serum markers of cholestasis, aminotransferases, and lipid and bile acid metabolism as well as inflammatory and immunological markers in patients with PBC. Fifteen patients with early-stage PBC and an incomplete biochemical response to ursodeoxycholic acid (UDCA) therapy (defined as alkaline phosphatase 1.5-fold above the upper limit of normal after 1 year) were treated with atorvastatin 10 mg/day, 20 mg/day, and 40 mg/day for 4 weeks, respectively. Serum levels of alkaline phosphatase increased during atorvastatin 20 mg and 40 mg ( P < 0.05), whereas leucine aminopeptidase and γ-glutamyltransferase remained unchanged. No statistical differences in overall serum ALT, AST, bilirubin, and IgM levels were observed. However, atorvastatin was discontinued in 1 out of 15 patients because of ALT 2-fold above baseline, and 2 patients showed ALT elevations 3-fold above the upper limit of normal at the end of the atorvastatin treatment period. Serum total cholesterol and low-density lipoprotein cholesterol levels decreased by 35% and 49%, respectively ( P < 0.001). Precursors of cholesterol biosynthesis (lanosterol, desmosterol, lathosterol) showed a similar pattern. No changes in serum bile acid levels and composition were observed during treatment. Conclusion: Atorvastatin does not improve cholestasis in PBC patients with an incomplete biochemical response to UDCA but effectively reduces serum cholesterol levels. (Hepatology 2007.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · cited 1×
“Cholesterol (mg/dl) 237 48 170 37* 159 27* 156 45* 244 62 Triglycerides (mg/dl) 106 47 88 36 86 25† 91 46† 108 39 Phospholipids (mg/dl) 300 50 245 53* 236 39* 236 54* 304 67 Apolipoprotein AI (mg/dl) 188 20 180 32 178 24* 174 24† 188 32 Apolipoprotein B (mg/dl) 115 29 75 18* 68 16* 66 27* 117 35 Lipoprotein(a) (mg/dl)…”
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“Cholesterol (mg/dl) 237 48 170 37* 159 27* 156 45* 244 62 Triglycerides (mg/dl) 106 47 88 36 86 25† 91 46† 108 39 Phospholipids (mg/dl) 300 50 245 53* 236 39* 236 54* 304 67 Apolipoprotein AI (mg/dl) 188 20 180 32 178 24* 174 24† 188 32 Apolipoprotein B (mg/dl) 115 29 75 18* 68 16* 66 27* 117 35 Lipoprotein(a) (mg/dl)…”
Wagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology · doi:10.1002/hep.20784 · Cited by 355 · cited 1×
“Cholesterol (mg/dl) 237 48 170 37* 159 27* 156 45* 244 62 Triglycerides (mg/dl) 106 47 88 36 86 25† 91 46† 108 39 Phospholipids (mg/dl) 300 50 245 53* 236 39* 236 54* 304 67 Apolipoprotein AI (mg/dl) 188 20 180 32 178 24* 174 24† 188 32 Apolipoprotein B (mg/dl) 115 29 75 18* 68 16* 66 27* 117 35 Lipoprotein(a) (mg/dl)…”
Self-citationHyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
Longo, M., Crosignani, A., Battezzati, P. M., Squarcia Giussani, C., Invernizzi, P., Zuin, M., & Podda, M. (2002) · Gut · doi:10.1136/gut.51.2.265 · Cited by 190
Hypercholesterolemia and Atherosclerosis in Primary Biliary Cirrhosis: What Is the Risk?
Crippin, J. S., Lindor, K. D., Jorgensen, R., Kottke, B. A., Harrison, J. M., Murtaugh, P. A., & Dickson, R. E. (1992) · Hepatology · doi:10.1002/hep.1840150518 · Cited by 149
Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers
Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00006-5 · Cited by 94
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Other drugs Malotilate [46], thalidomide [47], silymarin [48] and atorvastatin [49] were not effective in the treatment of PBC.”
BackgroundFrom the metabolic syndrome to NAFLD or vice versa?
Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H., & Svegliati-Baroni, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.016 · Cited by 497
Abraldes, J. G., Albillos, A., Bañares, R., Turnes, J., González, R., García–Pagán, J. C., & Bosch, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.043 · Cited by 471
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Metadata
- Authors
- Stojakovic, T., Putz-Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Stadlbauer, V., Gurakuqi, G., Stauber, R. E., März, W., & Trauner, M.
- Venue
- Hepatology
- Published
- 2007-09
- Volume
- 46
- Issue
- 3
- Pages
- 776-784
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2008882355
- Cited by
- 85
- References
- 10
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. https://app.cochat.ai/papers/10.1002/hep.21741
- The paper
- Stojakovic, T., Putz-Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Stadlbauer, V., Gurakuqi, G., Stauber, R. E., März, W., & Trauner, M. (2007). Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. https://doi.org/10.1002/hep.21741
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.